UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) will report second quarter 2023 financial results on Thursday, August 10, 2023, followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

Conference Call and Webcast Scheduled for Thursday, August 10, 2023 at 10:00 AM ET

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2023 financial results on Thursday, August 10, 2023, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product Jelmyto® (mitomycin) for pyelocaliceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter,@UroGenPharma.

Jelmyto^®, RTGel^® and UroGen^® are registered trademarks of UroGen Pharma Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802943779/en/

INVESTOR CONTACT:

Vincent Perrone

vincent.perrone@urogen.com

(609) 460-3588



MEDIA CONTACT:

Cindy Romano

Cindy.romano@urogen.com

(609) 460-3583

Source: UroGen Pharma Ltd.

FAQ

What is the date of UroGen Pharma Ltd.'s second quarter 2023 financial results report?

UroGen Pharma Ltd. will report its second quarter 2023 financial results on Thursday, August 10, 2023.

Where can I access the live audio webcast and conference call for UroGen Pharma Ltd.'s financial results report?

The live audio webcast and conference call for UroGen Pharma Ltd.'s financial results report can be accessed on UroGen's Investor Relations website.

How long will the replay of the webcast be available?

The replay of the webcast will be available on UroGen's Investor Relations website for approximately 30 days.